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Abstract
Background: Various trajectories for lung function and bronchial hyper‐reactivity 
(BHR) from early childhood to adulthood are described, including puberty as a period 
with	excessive	lung	growth.	Bronchiolitis	in	infancy	may	be	associated	with	increased	
risk of developing chronic obstructive pulmonary disease, but the development of 
respiratory patterns during puberty is poorly characterized for these children. We 
aimed to study the development and trajectories of lung function and BHR from 11 
to	18	years	of	age	in	children	hospitalized	for	bronchiolitis	in	infancy.
Methods: Infants	hospitalized	for	bronchiolitis	at	the	University	Hospitals	in	Stavanger	
and	Bergen,	Norway,	during	1997‐1998,	and	an	age‐matched	control	group,	were	in‐
cluded	in	a	longitudinal	follow‐up	study	and	examined	at	11	and	18	years	of	age	with	
spirometry and methacholine provocation test (MPT). The MPT data were managed 
as dose‐response slope (DRS) in the statistical analyses. Changes in lung function and 
DRS	from	11	to	18	years	of	age	were	analyzed	by	generalized	estimating	equations,	
including interaction terms.
Results: z‐scores	 for	 forced	 vital	 capacity	 (FVC),	 forced	 expiratory	 volume	 in	 first	
second (FEV1), FEV1/FVC	ratio,	and	DRS	were	not	different	from	11	to	18	years	of	
age in both the post‐bronchiolitis and the control group. The trajectories from 11 to 
18	years	did	not	differ	between	the	two	groups.	BHR	at	age	11	was	independently	
associated	with	asthma	at	age	18.
Conclusion: Children hospitalized for bronchiolitis had stable predicted lung function 
and	BHR	from	11	to	18	years	of	age.	The	lung	function	trajectories	were	not	different	
from controls.
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1  | INTRODUC TION
Longitudinal cohort studies have shown that the lung function tra‐
jectories throughout a life course vary between individuals and that 
abnormal lung function trajectories may originate in early life.1‐3 This 
has been shown both in unselected populations2,4 and after infant 
respiratory disease such as bronchopulmonary dysplasia associated 
with	extreme	prematurity.5	It	has	therefore	been	hypothesized	that	
chronic	obstructive	pulmonary	disease	(COPD)	may	begin	 in	child‐
hood, conceivably precipitated by interactions between genetic pre‐
dispositions, disadvantageous intrauterine environments, or early 
respiratory insults.6
Worldwide, bronchiolitis represents a substantial health burden 
for infants, and it is the most common cause for hospitalization during 
infancy in developed countries.7 These children have increased risk 
of developing asthma, low lung function, and increased bronchial 
hyper‐reactivity (BHR) both during childhood8‐11 and adulthood,12‐14 
and	possibly	 increased	risk	of	developing	COPD.6 However, we do 
not know the nature of this association, that is, if it is the bronchi‐
olitis per se that alters the pattern of lung development or if both 
disorders are caused by inherent predispositions or vulnerabilities 
of genetic or antenatal origin. Puberty is the period of life with the 
most	excessive	lung	growth,1,15 but we do not know if bronchiolitis 
in infancy modulates the development of airway size and hyper‐re‐
activity during the pubertal growth spurt.
We have previously reported lung function data in a cohort of 
11‐year‐old	 children	 hospitalized	 for	 bronchiolitis	 in	 1997‐1998.10 
The	present	study	is	based	on	examinations	of	the	same	subjects	at	
age	18	years.	We	aimed	to	study	if	lung	function	and	BHR	changed	
from	11	to	18	years	of	age	in	children	hospitalized	for	bronchiolitis	
in infancy, and whether lung function trajectories during this period 
was different from an age‐matched control group.
2  | METHODS
Originally,	131	children	hospitalized	for	bronchiolitis	during	their	first	
year	of	life	during	the	winter	seasons	1997	and	1998	at	the	University	
Hospitals in Stavanger and Bergen, Norway, were included in a lon‐
gitudinal prospective follow‐up study.16 Bronchiolitis was defined as 
an acute viral respiratory tract infection during the first year of life 
with	fever,	tachypnea,	dyspnea,	prolonged	expiration,	and	wheeze	on	
auscultation.17	 In	order	to	avoid	 including	children	with	other	condi‐
tions such as viral‐induced wheezing and asthma, only children below 
Key Message
Children hospitalized for bronchiolitis in infancy had sta‐
ble predicted lung function and bronchial hyper‐reactivity 
(BHR)	 from	11	 to	18	years	of	age.	Lung	 function	 trajecto‐
ries were significantly lower, but parallel to that of an age‐
matched control group, suggesting that children with former 
bronchiolitis follow a lung function trajectory below normal 
peak values during puberty, but that the development be‐
tween	11	and	18	years	of	age	is	parallel	to	healthy	controls	
with no catch up nor decline. BHR at age 11 was associated 
with	 asthma	 at	 age	 18.	 Children	with	 severe	 bronchiolitis	
in infancy could benefit from regular clinical follow‐ups to 
monitor lung function and development of asthma.
F I G U R E  1   Flowchart of the study population, consisting of children hospitalized for bronchiolitis in infancy and an age‐matched control 
group.	The	invited	children	participated	in	the	11‐y	examination.	18	y,	Second	follow‐up	at	median	18	years	of	age;	MPT,	Methacholine	
provocation test. †For one participant, only forced vital capacity (FVC) was considered valid, making n = 31 in calculations of other lung 
function variables
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12 months of age were included.7 At hospitalization, nasopharyngeal 
mucus	was	 examined	 for	 respiratory	 syncytial	 virus	 (RSV)	 by	 direct	
immunofluorescence	 (bioMèrieux,	 Marcy‐l’Ètoile,	 France).	 Children	
testing positive for RSV were defined as RSV‐positive, the others were 
defined as RSV‐negative.
One‐hundred	 and	 twenty‐one	 children	 (92%)	 participated	 in	 a	
first follow‐up at 11 years of age, together with an age‐matched con‐
trol	group	of	141	children.	The	control	group	included	children	born	
in	1997	with	no	previous	history	of	hospitalization	for	bronchiolitis	
recruited from three different schools in Stavanger, Norway. The 11‐
year	examination	included	questionnaires	and	tests	for	atopic	sensi‐
tization, lung function, and BHR, as previously reported.10
All participants from the original study were invited to a second fol‐
low‐up	at	approximately	18	years	of	age,	including	questionnaires	and	
clinical tests of lung function, BHR, and atopic sensitization. This study 
presents results from the children participating at both follow‐ups. A 
total	of	108	children	from	the	post‐bronchiolitis	group	and	89	children	
from	the	age‐matched	control	group	at	the	11‐year	examination	were	
invited to participate in this substudy (Figure 1).
2.1 | Lung function, BHR, and atopic sensitization
At both follow‐ups, lung function was measured by spirometry 
according to established guidelines,18	 using	 Vmax	 Encore	 229D	
spirometer	 (SensorMedics	 Inc),	 with	 data	 standardized	 for	 age,	
height,	 and	 sex.19	 Results	 were	 presented	 as	 z‐scores	 and	 %	
predicted.
Bronchial hyper‐reactivity was measured by methacho‐
line provocation test (MPT) performed with an inhalation‐syn‐
chronized dosimetric nebulizer, providing baseline FEV1	 >	 65%	
predicted.20,21 The test continued until a fall in FEV1	of	>20%	com‐
pared with baseline FEV1,	 or	until	 a	maximal	 cumulative	dose	of	
11.5 µmol methacholine had been administered. A dose–response 
slope	 (DRS)	 was	 calculated	 as	 the	 ratio	 of	 maximal	 percentage	
decline in FEV1 from baseline to cumulative administered dose of 
methacholine	(%/µmol).22
Atopic sensitization was assessed by using skin prick tests ac‐
cording to guidelines23 and by measuring specific immunoglobulin E 
(IgE).	For	details,	see	Appendix	1.
  
Post‐bronchiolitis 
group
N = 60
Control group
N = 40 P‐value* 
Boys	(%) 29	(48.3) 21 (52.5) .683
Age at hospitalization, mo 4.0	(1.8,	6.2)   
RSV‐positive	bronchiolitis,	n	(%) 50	(83.3)   
Personal	smoking,	n	(%) 4	(6.7) 1 (2.5) .349
Ever	household	smoking,	n	(%) 21 (35.0) 8	(20.0) .105
Family	history	of	atopy,	n	(%) 45	(75.0) 22 (55.0) .037
First follow‐up at 11 y
Age, y 11.3	(11.0,	11.7) 11.8	(11.3,	12.1) .001
Height, cm 148.5	(144.0,	153.8) 149.0	(146.0,	155.8) .459
Weight, kg 38.3	(35.0,	45.4) 40.0	(35.3,	44.9) .625
Current	asthma,	n	(%) 9 (15.0) 5 (12.5) .724
Allergic	sensitization,	n	(%) 12 (20.0) 17	(42.5) .015
Second follow‐up at 18 y
Age, y 18.0	(17.0,	18.0) 18.0	(17.0,	18.0) .100
Height, cm 172.4	(164.4,	180.9) 173.8	(166.5,	181.2) .635
Weight, kg 65.9	(59.9,	75.9) 63.2	(57.8,	72.4) .233
Current	asthma,	n	(%) 18	(30.0) 9 (22.5) .408
Asthma	ever,	n	(%) 23	(38.3) 10 (25.0) .249
Allergic	sensitization,	n	(%)†  13	(24.1) 20	(60.6) .001
Allergic	rhinoconjunctivitis,	n	(%) 28	(46.7) 24	(60.0) .191
Atopic	dermatitis	ever,	n	% 15 (25.0) 14	(35.0) .280
Note: aBold values denote statistical significance at the P < 0.05 level. 
Data	are	presented	as	medians	(interquartile	ranges)	unless	otherwise	stated.
Abbreviations: RSV, Respiratory syncytial virus.
*P‐values from Mann–Whitney U test	for	continuous	variables	and	Pearson's	chi‐square	test	for	
dichotomous variables. 
†54	subjects	in	the	post‐bronchiolitis	group	and	33	controls	underwent	allergy	tests	at	the	second	
follow‐up	at	18	y.	
TA B L E  1   Clinical characteristics at 
11	and	18	years	in	children	hospitalized	
for bronchiolitis in infancy and an age‐
matched control group
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2.2 | Data collection and definitions
Asthma symptoms and medications during the last year were re‐
ported	by	the	parents	(11‐year	examination)	and	study	subjects	(18‐
year	 examination)	 from	 questionnaires	 based	 on	 the	 International	
Study	of	Asthma	and	Allergies	 in	Childhood	(ISAAC).24	In	addition,	
at	18	years	more	detailed	data	regarding	personal	and	family	history	
of	asthma	and	atopy	were	collected	through	questionnaires	and	sup‐
plemented with information from medical records at hospitalization. 
For	details,	see	Appendix	1.
Asthma ever was defined as positive answer to have you ever 
been diagnosed with asthma? Current asthma was defined as asthma 
ever combined with a positive answer to at least one of the two 
questions:	(a)	Have you during the last 12 months had heavy breathing 
or wheezing/chest‐tightness and (b) Have you during the last 12 months 
used any asthma medications (inhaled corticosteroids, long‐ or 
short‐acting beta‐2 agonists, montelukast, ipratropium bromide, or 
any combinations).
2.3 | Ethics
The study was approved by the Regional Committee on Medical 
Research Ethics. Signed statements of informed consent were ob‐
tained from all participants and from parents if the participants were 
younger	than	18	years	of	age.
2.4 | Statistical analysis
Continuous	variables	are	presented	as	group	means	with	95%	con‐
fidence intervals, and were compared by Student's t test or as medi‐
ans	 and	 interquartile	 range	 (IQR)	 and	 compared	by	Mann–Whitney	
U test, as appropriate. Categorical variables are presented as counts 
TA B L E  2  Lung	function	and	bronchial	hyper‐reactivity	at	11	and	18	years	in	children	hospitalized	for	bronchiolitis	in	infancy	and	an	age‐
matched control group
  
Post‐bronchiolitis group Control group
P‐value* N Observed mean (95% CI) N Observed mean (95% CI)
FEV1
z‐score 11 y 60 −0.44	(−0.67,	−0.21) 40 0.20	(−0.20,	0.61) .004
%	of	predicted   94.9	(92.3,	97.5)  102.2	(97.5,	107.0) .004
z‐score 18	y 53 −0.57	(−0.83,	−0.30) 31 0.15	(−0.28,	0.57) .003
%	of	predicted   93.3	(90.1,	96.5)  101.6	(96.7,	106.6) .003
FVC
z‐score 11 y 60 0.15	(−0.13,	0.43) 40 0.41	(−0.02,	0.83) .302
%	of	predicted   102.0	(98.7,	105.3)  105.1 (99.9, 110.2) .293
z‐score 18	y 53 −0.13	(−0.41,	0.15) 32 0.23	(−0.12,	0.59) .107
%	of	predicted   98.5	(95.2.	101.8)  102.8	(98.6.	107.0) .112
FEV1/FVC
z‐score 11 y 60 −0.86	(−1.17,	−0.54) 40 ‐0.36	(−0.69,	−0.03) .037
%	of	predicted   93.1	(90.7,	95.5)  97.1	(94.8,	99.4) .023
z‐score 18	y 53 −0.66	(−0.98,	−0.34) 31 ‐0.20	(−0.53,	0.13) .058
%	of	predicted   94.3	(91.8,	96.8)  98.2	(95.8,	100.6) .039
FEF	25‐75
z‐score 11 y 60 −1.00	(−1.28,	−0.72) 40 ‐0.38	(−0.69,	−0.06) .004
%	of	predicted   79.8	(74.2,	85.5)  92.1	(85.0,	99.2) .007
z‐score 18	y 53 −0.75	(−1.03,	−0.48) 31 ‐0.09	(−0.46,	0.28) .004
%	of	predicted   84.8	(79.2.	90.4)  99.1	(91.0.	107.3) .003
DRS† 
Geometric mean 11 y 58†  5.86	(3.76,	9.12) 39†  2.28	(1.33,	3.89) .008
Geometric mean 18	y 49 7.17	(4.31,	11.93) 31 2.58	(1.40,	4.75) .012
Note: DRS	(%/μmol)	is	the	ratio	of	maximum	percentage	decline	in	FEV1 from baseline to cumulative administered dose (μmol) of methacholine.
Abbreviations:	11	y,	First	follow‐up	at	median	11	years	of	age;	18	y,	Second	follow‐up	at	median	18	years	of	age;	CI,	Confidence	interval;	DRS,	
Methacholine dose–response slope; FEF25‐75,	Forced	expiratory	flow	between	25%	and	75%	of	the	forced	vital	capacity;	FEV1,	Forced	expiratory	
volume in first second; FVC, Forced vital capacity.
*P‐values from Student's t test. 
†Due	to	contraindications	in	two	subjects	in	the	post‐bronchiolitis	group	and	one	control,	methacholine	provocation	test	was	only	performed	in	58	
and 39 subjects, respectively, at 11 y. 
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and	percentages,	and	differences	were	tested	by	Pearson's	chi‐square	
test. Lung function and DRS to methacholine at both follow‐ups were 
compared	 by	 generalized	 estimating	 equations	 (GEE).	 Interaction	
terms (group*time) were applied to test divergent development of lung 
function and DRS between the post‐bronchiolitis and control group 
from	11	to18	years	of	age,	and	the	analyses	were	adjusted	for	atopic	
sensitization and asthma at 11 years of age as well as family history 
of asthma or atopy. The distribution of the DRS to methacholine was 
highly skewed and therefore transformed using the natural logarithm, 
after negative values were set to zero and 0.1 was added to all DRS 
values.	A	Cox	regression	analysis	allowing	for	correlation	between	re‐
peated tests of the same individuals was used to analyze the propor‐
tion of non‐responders at each cumulative dose of methacholine.
The association between BHR at 11 years and current asthma at 
18	years	was	analyzed	by	multivariable	logistic	regression	analysis.	
LnDRS	was	included	as	explanatory	variable,	and	the	analyses	were	
adjusted for the following covariates measured at 11 years: group 
variable, gender, z‐score FEV1, and current asthma.
Analyses	were	carried	out	using	SPSS	version	24.0	(IBM	Corp.)	
and Stata version 15.1 (StataCorp LLC). Generally, P‐values	 ≤	 .05	
were considered statistically significant.
3  | RESULTS
Sixty	 children	 (56%)	 in	 the	 post‐bronchiolitis	 group	 and	 40	 (45%)	
in	the	control	group	consented	to	participate,	and	54	 (50%)	 in	the	
post‐bronchiolitis	group	and	33	(37%)	controls	consented	to	clinical	
tests	at	the	18‐year	examination	(Figure	1).	One	control	and	one	in	
the post‐bronchiolitis group failed to complete spirometry according 
to	standard	quality	criteria,	leaving	53	(49%)	and	32	(36%)	individu‐
als	with	results	from	spirometry,	respectively.	One	control	had	low	
peak	expiratory	flow	and	only	acceptable	FVC,	and	not	valid	MPT.	In	
the post‐bronchiolitis group, MPT was not valid in one subject and 
not	performed	in	three	subjects	due	to	contraindications,	hence	49	
(45%)	participants	in	the	post‐bronchiolitis	group	and	31	(35%)	con‐
trols had acceptable MPT (Figure 1).
Baseline characteristics of both groups are presented in Table 1. 
There were no differences regarding, age, gender, weight, and length 
between	the	two	groups.	 In	the	post‐bronchiolitis	group,	83%	had	
been hospitalized with RSV‐positive bronchiolitis. Atopic sensitiza‐
tion was more common in the control group than in the post‐bron‐
chiolitis group at both follow‐ups.
3.1 | Lung function and bronchial hyper‐reactivity
Lung function and DRS to methacholine in both groups and at both 
ages are presented in Table 2. Children in the post‐bronchiolitis 
group had lower FEV1, FEV1/FVC, FEF25‐75, and higher DRS than 
controls at both follow‐ups.
For both groups, there were no significant changes in z‐
scores	 for	 forced	 vital	 capacity	 (FVC),	 forced	 expiratory	 vol‐
ume in first second (FEV1), or FEV1/FVC ratio between 11 and 
18	 years	 of	 age	 (Table	 3).	 In	 the	 post‐bronchiolitis	 group,	 but	
not	 in	 the	 control	 group,	 z‐scores	 for	 forced	 expiratory	 flow	
between	25%	and	75%	of	FVC	(FEF25‐75)	was	higher	at	18	than	
TA B L E  3  Change	in	lung	function	variables	from	11	to	18	y	of	age	in	children	hospitalized	for	bronchiolitis	in	infancy	and	an	age‐matched	
control	group,	presented	as	mean	change	with	95%	CI
 
Post‐bronchiolitis Controls Interaction
Mean change (95% CI) P‐value*  Mean change (95% CI) P‐value*  P‐value* 
FEV1, z‐score ‐0.09	(−0.31,	0.13) .442 ‐0.14	(−0.53,	0.25) .484 .816
FEV1, z‐score
†  ‐0.08	(−0.30,	0.14) .454 ‐0.15	(−0.55,	0.24) .451 .765
FVC, z‐score ‐0.24	(−0.51,	0.03) .076 ‐0.24	(−0.61,	0.13) .203 .997
FVC, z‐score†  ‐0.23	(−0.49,	0.04) .089 ‐0.26	(−0.63,	0.12) .182 .911
FEV1/FVC, z‐score 0.18	(−0.14,	0.50) .263 0.10	(−0.22,	0.42) .529 .731
FEV1/FVC, z‐score
†  0.17	(−0.15,	0.49) .301 0.12	(−0.20,	0.43) .471 .819
FEF25‐75, z‐score 0.25 (0.00, 0.50) .046 0.21	(−0.13,	0.54) .236 .834
FEF25‐75, z‐score
†  0.24	(−0.00,	0.49) .054 0.21	(−0.13,	0.55) .230 .873
LnDRS 0.17	(−0.29,	0.64) .465 0.11	(−0.42,	0.64) .697 .851
LnDRS†  0.17	(−0.29,	0.63) .471 0.10	(0.43,	0.62) .721 .835
Note: Bold values denote statistical significance at the P < 0.05 level. 
DRS	(%/μmol)	is	the	ratio	of	maximum	percentage	decline	in	FEV1 from baseline to cumulative administered dose (μmol) of methacholine. Due to 
highly skewed distribution, DRS was transformed using the natural logarithm. The group‐wise mean changes were estimated in generalized estimat‐
ing	equation	(GEE)	models	including	interaction	terms	group*time	to	test	for	unequal	trajectories	in	controls	and	post‐bronchiolitis.	A	positive	mean	
change	indicates	that	z‐scores	were	higher	at	18	than	11	y	of	age.
Abbreviations:	CI,	Confidence	interval;	DRS,	Methacholine	dose–response	slope;	FEF25‐75,	Forced	expiratory	flow	between	25%	and	75%	of	the	
forced vital capacity; FEV1,	Forced	expiratory	volume	in	first	second;	FVC,	Forced	vital	capacity.
*P‐values from Wald test. 
†Adjusted for family history of asthma or atopy, atopic sensitization at 11 y of age, and asthma at 11 y of age 
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11 years of age. Change in absolute lung function variables from 
11	to	18	years	of	age	 is	presented	 in	Table	S1	and	commented	
in	Appendix	2.	We	found	no	significant	interaction	between	age	
and group, meaning that the trajectories of lung function and 
DRS	from	11	to	18	years	of	age	did	not	differ	between	the	post‐
bronchiolitis and the control group neither in the unadjusted 
nor in the adjusted analyses (Table 3, Table S1, Figures 2 and 
3). Furthermore, there were no significant interactions between 
age, group, and gender, that is, we found no differences between 
boys and girls in how bronchiolitis in infancy affected the trajec‐
tories	of	 lung	 function	and	BHR	 from	11	 to	18	years.	Figure	3	
displays	the	methacholine	responsiveness	at	11	and	18	years	of	
age. There was no significant interaction effect between group 
and	age	by	Cox	 regression	 (P	 =	 .988)	or	 from	 the	GEE	analysis	
(Table 3), and we found no differences in the trajectories for 
DRS	from	11	to	18	years	of	age	between	the	post‐bronchiolitis	
and control groups.
In	 the	multivariable	 logistic	 regression	analysis,	BHR	at	age	11	
was	 independently	 associated	with	 current	 asthma	 at	 age	 18	 (OR	
1.88;	95%	CI	1.22‐2.89,	P	=	.004).
4  | DISCUSSION
The present study shows that lung function z‐scores and BHR were 
stable	from	11	to	18	years	of	age	in	children	hospitalized	for	bron‐
chiolitis during their first year of life, and that the trajectories for 
lung	function	and	BHR	from	11	to	18	years	of	age	were	not	different	
from the control group. These results applied for both boys and girls. 
BHR	at	age	11	was	independently	associated	with	asthma	at	age	18.
In	this	rather	small	cohort,	lung	function	was	lower	and	BHR	was	
higher after bronchiolitis in infancy compared to age‐matched con‐
trols	with	no	such	history	both	at	11	and	at	18	years	of	age.	This	is	
in line with previous follow‐up studies during childhood,10,11,25 and a 
F I G U R E  2   z‐scores	for	lung	function	variables	presented	as	estimated	marginal	means	with	95%	confidence	intervals	at	11	and	18	y	of	
age	in	subjects	hospitalized	for	bronchiolitis	in	infancy	and	controls.	Results	from	generalized	estimating	equation	(GEE)	analysis.	The	x‐axis	
depicts age, and the y‐axis	depicts	mean	z‐scores.	The	black	lines	represent	spirometric	scores	for	the	post‐bronchiolitis	group	and	the	gray	
lines	represent	spirometric	scores	for	the	control	group.	11	y:	First	follow‐up	at	median	11	years	of	age;	18	y,	Second	follow‐up	at	median	
18	years	of	age;	FEV1,	Forced	expiratory	volume	in	first	second;	FVC,	Forced	vital	capacity;	FEF25‐75,	Forced	expiratory	flow	between	25%	
and	75%	of	the	forced	vital	capacity
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similar pattern has also been shown in adults with a history of bron‐
chiolitis in early childhood.13,14,26 However, this issue was not the 
focus of the present study, rather our aim was to study the trajecto‐
ries of lung function and BHR during the important pubertal growth 
spurt.
Although there are suggestions that childhood respiratory ill‐
nesses,	such	as	viral	bronchiolitis,	predispose	to	subsequent	asthma	
and	COPD,6 only a few longitudinal studies include repeated mea‐
surements of lung function and/or BHR during childhood and up 
to young adulthood in children hospitalized for bronchiolitis in in‐
fancy.12‐14 As far as we know, none of these previous post‐bronchiol‐
itis studies have investigated lung function and/or BHR longitudinally 
during the important transitional period from childhood to young 
adulthood.
During childhood and adolescence, the lung function trajectories 
are characterized by a growth phase reaching a peak after puberty at 
18‐25	years	of	age,	followed	by	a	plateau	phase,	and	finally	a	decline	
linked to physiological aging.1 Some children following a trajectory 
below normal may have catch‐up of lung function during child‐
hood and adolescence.1 Unselected population cohort studies have 
shown	that	lung	function	trajectories	contributing	to	COPD	include	
both early and persistent low lung function as well as accelerated 
decline in adulthood.3 The results from the present study suggest 
that children with former bronchiolitis during puberty follow a lung 
function trajectory below normal peak values, but that the develop‐
ment	between	11	and	18	years	of	age	is	parallel	to	healthy	controls	
with no catch‐up nor decline. The results support a notion that low 
lung function and increased BHR, which has been observed at differ‐
ent ages after bronchiolitis, are features that are established in early 
life, either due to airway damage caused by the respiratory insult 
during bronchiolitis or that these abnormalities are already present 
prior to the respiratory event, as also suggested by others.6 The ac‐
celerated growth and pubertal period is also characterized by a shift 
from male‐dominated childhood asthma to female‐dominated adult 
asthma.15,27 We did not find that gender affected the impact of for‐
mer bronchiolitis on the lung function trajectories during puberty.
Similar lung function trajectories, as observed in the present 
study, have been found in young adults/adolescents after other 
early respiratory insults such as repeated episodes of viral wheeze 
and	 extreme	 prematurity.4,5 The Tucson cohort included children 
with viral wheeze up to the age of 3 years, and found that patterns of 
wheezing prevalence and levels of lung function were established by 
the	age	of	six	and	did	not	change	significantly	by	the	age	16	years.4,28 
Similarly, a Norwegian longitudinal cohort study from mid‐childhood 
to	adulthood	showed	that	individuals	born	extremely	preterm	con‐
sistently had lower lung function and increased BHR compared to 
term‐born controls, and that the trajectories from 10 to 25 years of 
age were parallel and irrespective of the degree of bronchopulmo‐
nary dysplasia.5
We found a tendency for increased z‐scores for FEF25‐75 from 
11	 to	18	years	 in	 the	post‐bronchiolitis	group,	but	when	 tested	 in	
interaction terms, this development did not differ from the control 
group. The finding must be further elaborated in larger longitudinally 
studies, but may at least support that lung function does not decline 
in this group during puberty.
Bronchiolitis	is	associated	with	subsequent	asthma	both	in	children	
and adults, and BHR is a fundamental characteristic of asthma.10,13 We 
found	 that	BHR	was	 stable	 from	11	 to	18	years	of	 age	 in	 the	post‐
bronchiolitis group, and the trajectory did not differ from controls. 
However, we found that BHR at 11 years was associated with current 
F I G U R E  3   Bronchial hyper‐reactivity 
to	methacholine	at	11	and	18	years	of	age	
in subjects hospitalized for bronchiolitis 
in infancy and controls. The x‐axis	depicts	
total cumulative dose of methacholine 
given to each subject, censored at the 
maximum	given	dose	of	11.5	µmol.	The	
y‐axis	depicts	the	proportion	of	non‐
responders at each given dose. 11 y, First 
follow‐up	at	median	11	years	of	age;	18	y,	
Second	follow‐up	at	median	18	years	of	
age
Cumulative dose of methacholine (µmol)
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asthma	at	18	years,	also	when	adjusting	for	asthma	at	age	11.	The	asso‐
ciation	between	BHR	and	subsequent	asthma	is	in	line	with	the	results	
from a Norwegian unselected birth cohort study.29 The finding sup‐
ports the speculation that BHR might be an independent and possibly 
inborn feature that can be causally related to bronchiolitis as well as to 
subsequent	development	of	asthma.30,31 The clinical implication could 
be that children with severe BHR may benefit from regular clinical fol‐
low‐ups to monitor if asthma develops later in life.
4.1 | Strength and limitations
The main strength of this study is the longitudinal design, and the 
main weakness is the modest participation rate and power, increas‐
ing the risk of selection bias and false‐negative results. The lack of 
lung function data from infancy and early childhood precluded as‐
sessment of studying tracking from early life.
5  | CONCLUSION
This longitudinal study shows that lung function z‐scores and BHR 
were	stable	from	11	to	18	years	of	age	in	children	hospitalized	for	bron‐
chiolitis in infancy, following trajectories that were significantly lower, 
but parallel to those of the control group in both boys and girls. BHR at 
age	11	was	associated	with	asthma	at	age	18.	Further	long‐term	follow‐
up	studies	are	needed	to	study	if,	and	possibly	to	what	extent,	children	
with	former	bronchiolitis	have	increased	risk	of	developing	COPD.
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APPENDIX 1
ATOPIC SENSITIZ ATION
Atopic sensitization at 11 years of age was defined by a positive skin 
prick	test	(SPT)	for	at	least	one	allergen	(wheal	diameter	≥3	mm	larger	
than	the	negative	control),	and	at	18	years	of	age	as	a	positive	SPT	or	
specific	immunoglobulin	E	(IgE)	≥	0.35	kU/L	for	at	least	one	allergen.	
Both tests included the following allergens: Dermatophagoides ptero‐
nyssinus, dog and cat dander, Cladosporium herbarium, birch, timothy, 
egg white, milk, peanut, hazelnut, and codfish. The SPT was per‐
formed with Soluprick® allergens (ALK Albello, Hørsholm, Denmark). 
Histamine	(10	mg/mL)	was	used	as	a	positive	control	and	a	0.9%	sa‐
line	solution	as	a	negative	control.	For	analysis	of	specific	IgE,	blood	
was	drawn	and	serum	stored	at	−70°C	and	analyzed	by	Phadiatop®, 
fx5E®,	 and	 by	 specific	 IgE	 when	 positive	 at	 the	 Department	 of	
Medical Biochemistry, Stavanger University Hospital.
DEFINITIONS AND QUE S TIONNAIRE S
At	the	18‐year	examination,	more	detailed	data	regarding	personal	
and family history of asthma and atopy were collected through 
questionnaires	 and	 supplemented	 with	 information	 from	 medi‐
cal records at hospitalization. Atopic dermatitis was defined as a 
positive answer to have you ever had atopic dermatitis. Family his‐
tory of asthma or allergic diseases was defined as a positive an‐
swer to do you know if your mother, father, or siblings have or have 
had atopic dermatitis, asthma, or positive allergy tests. Ever house‐
hold smoking was defined as a positive answer to do/did anyone 
smoke in your home. Smoking in participants was defined as a posi‐
tive answer to do you smoke. Allergic rhinoconjunctivitis was de‐
fined as a positive answer to have you ever had runny or itching nose 
and/or eyes apart from colds.
APPENDIX 2
CHANG E IN ABSOLUTE LUNG FUNC TION
The	change	in	lung	function	between	11	and	18	years	adjusted	for	
gender,	 age,	 and	 height	 is	 best	 expressed	 by	 z‐scores	 as	 given	 in	
the article (Table 3). As the changes in absolute lung function may 
add some clinical information, these are presented in Table S1. The 
results show that the absolute lung function values apart from the 
ratio	for	FEV1/FVC	were	higher	at	18	than	11	years	of	age.	In	line	
with the results from the analyses using z‐scores, there were no sig‐
nificant interaction effects between age and group, underlining that 
the	changes	in	lung	function	from	11	to	18	years	did	not	differ	be‐
tween the control and post‐bronchiolitis group.
